All In Biotech

Drug Trial Radar · NCT05743179

The Effect of Zoledronate on the Prevention of Pneumonia in Hip Fracture Patients

The Effect of Zoledronate on the Prevention of Pneumonia in Hip Fracture Patients (Zoo-P): An Open-label, Pragmatic, Randomised Controlled Trial

Last checked: Nov 19, 2026Latest source record: Feb 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 2,692 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

2,692

Planned (sponsor's estimate)

Start

Dec 5, 2022

Primary completion

May 2025

Study completion Jun 2025

Sponsor

Lead sponsor
The University of Hong KongAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Queen Mary Hospital, Hong Kong; Caritas Medical Centre, Hong Kong; Prince of Wales Hospital, Shatin, Hong Kong; United Christian Hospital
First posted
Feb 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Nitrogen-containing bisphosphonates (N-BPs; such as alendronate and zoledronate) are commonly used in the treatment of osteoporosis and fracture prevention, in which zoledronate has a proven better efficacy than alendronate. In 2018, our real-world propensity score matched study showed that the use of N-BPs was significantly associated with reduced risk of myocardial infarction and stroke in hip fracture patients. In addition to cardiovascular diseases, both preclinical study and sensitivity analysis also suggest evidence for N-BPs in pneumonia prevention. Moreover, a pragmatic clinical trial is developed to evaluate effect of the tested intervention in real-life routine clinical practice since traditional explanatory radomised controlled trial (RCT) may have poor generalizability due to highly selected patients and controlled environments. This study aims to evaluate if zoledronate reduces risk of pneumonia in hip fracture patients using pragmatic clinical trial approach. This is an open-label, multi-centre, pragmatic, randomised controlled trial. Patients will be recruited from 4 hospitals, namely Caritas Medical Centre, Prince of Wales Hospital, Queen Mary Hospital, and United Christian Hospital. Age, sex, body mass index, eGFR, history of fracture, chronic respiratory diseases, and other medical history, will be measured and recorded at recruitment.

Conditions

  • Hip Fractures
  • Pneumonia

Interventions

  • ZoledronateDrug

    Aclasta Solution for Infusion 5mg/100ml (zoledronic acid)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pneumonia hospitalizationsTime frame: 12 months

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Queen Mary Hospital

    Hong Kong, Hong Kong · Recruiting

  • United Christian Hospital

    Kwun Tong, Hong Kong · Recruiting

  • Caritas Medical Centre

    Sham Shui Po, Hong Kong · Recruiting

  • Prince of Wales Hospital

    Shatin, Hong Kong · Not yet recruiting

  • Tai Po Hospital

    Tai Po, Hong Kong · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.